CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
The Pharma Data
AUGUST 11, 2020
In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Institute hormone replacement therapy for endocrinopathies as warranted. Immune-Mediated Pneumonitis.
52 
Let's personalize your content